



Press release

## Valbiotis – Combined Annual Shareholders General Meeting held on May 2, 2023

La Rochelle, May 3, 2023 (8:30 a.m CEST) – Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, **announces its Combined Annual Shareholders Meeting was held on May 2, 2023 at Espace Encan, La Rochelle, under the chairmanship of Sébastien PELTIER, Chairman of the Board of Directors.**

All resolutions were adopted by a very large majority of shareholders, with the exception of resolutions 10 to 13 and 16 to 19 presented on an extraordinary basis.

Shareholders voted in particular to renew the terms of office of two of the members of the Supervisory Board and extend the terms of office of all members of the Board of Directors and the Supervisory Board from three to four years.

Sébastien PELTIER, co-founder, Chairman of the Board of Directors at Valbiotis, comments: *“On behalf of the Board of Directors of Valbiotis, I would like to express our gratitude to our shareholders for the trust they have shown us during this General Meeting by adopting almost all the resolutions. This demonstrates their commitment to our business plan and our strategic vision for the future. With the renewed support of our shareholders, we are ready to meet the challenges ahead of us and continue our development in a promising market environment and looking forward to communicating on the next key steps, including the results of the Phase II/III Reverse-It study on TOTUM•63, expected before the end of the first semester 2023<sup>1</sup>. We are perfectly in line with the announced schedule and prepared to advance alongside our shareholders to make Valbiotis a leading company in the field of healthcare.”*

All information related to this Shareholders’ Meeting is available at: <https://www.valbiotis.com/en/general-assemblies/>.

### About Valbiotis

Valbiotis is a commercially oriented Research & Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.

Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.

Internationally, its products are intended to be the subject of licensing and/or distribution agreements with global or regional health and nutrition players. In France, Valbiotis will be responsible for marketing its own products.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information about Valbiotis, please visit: [www.valbiotis.com](http://www.valbiotis.com)



## ↳ Contacts

### Corporate communication

#### **Valbiotis**

**Carole ROCHER**

Communication  
and Public Affairs Director  
+33 6 77 82 56 88

#### **Marc DELAUNAY**

Communication Manager  
[media@valbiotis.com](mailto:media@valbiotis.com)

### Financial communication

#### **Seitosei Actifin**

**Stéphane RUIZ**

Associate Director  
+33 1 56 88 11 14  
[sruiz@actifin.fr](mailto:sruiz@actifin.fr)



Name: Valbiotis  
ISIN code: FR0013254851  
Ticker symbol: ALVAL  
EnterNext© PEA-SME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document filed to the French Financial Markets Regulator (AMF) on April 26, 2023, this document is available on the Company's website ([www.valbiotis.com](http://www.valbiotis.com)). This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.

